argenx reported global net product sales of $1.7 billion for VYVGART, representing 54% year-over-year growth.
The company also announced positive topline results from its Phase 3 ALKIVIA trial in immune-mediated necrotizing myopathy, with plans to submit a supplemental biologics license application by year-end.
